TerSera Therapeutics today announced the presentation of positive data from its study of preventing hypersensitivity infusion reactions. Deerfield, Ill.-based TerSera’s intravenous (IV) cetirizine injection was pitted against IV diphenhydramine in preventing hypersensitivity infusion reactions in patients with breast cancer and other malignancies, according to a news release. The randomized, double-blind Phase 2 study evaluated TerSera’s […]